Peptide Glossary: 200+ Research and Pharmacology Terms

A reference for terminology used in peptide chemistry, receptor biology, pharmacology, analytical testing, and clinical research. The glossary explains what a term means; it does not turn a mechanism, research compound, or product listing into evidence of safety or effectiveness.

Terms are organized by subject and alphabetically within each section. Approval examples and regulatory definitions are reviewed as of the date above because those details can change.

Start with these distinctions

For editorial interpretation, see the research methodology. For topic-level evidence, browse the use-case map or research library. For product documentation concepts, use the purity testing guide and sourcing guide. The source directory reports availability and batch documentation; inclusion is not an endorsement.

Jump to a category

• Receptors
• Signaling pathways
• Molecular biology
• Cell biology
• Pharmacology
• Peptide chemistry
• Aging and longevity
• Hormones and endocrinology
• Disease and condition terms
• Research methods
• Common acronyms

---

Receptors

AMPA Receptor

Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors are ionotropic glutamate receptors that mediate fast synaptic transmission in the CNS. They work in concert with NMDA receptors to regulate synaptic strength and plasticity. AMPA receptor trafficking to and from the synapse is a key mechanism underlying long-term potentiation (LTP) and memory formation.

BMP Receptor

Bone morphogenetic protein receptors are serine/threonine kinase receptors that bind BMPs, a subgroup of the TGF-beta superfamily. They play essential roles in bone and cartilage formation, embryonic development, and tissue homeostasis. BMP signaling through these receptors activates SMAD1/5/8 transcription factors to regulate osteoblast differentiation and skeletal patterning.

Calcitonin Receptor

A G protein-coupled receptor (GPCR) that binds the hormone calcitonin, primarily expressed in osteoclasts and kidney cells. Activation inhibits osteoclast-mediated bone resorption, making it a target in osteoporosis research. The receptor also modulates renal calcium handling and has been studied in relation to amylin signaling when complexed with receptor activity-modifying proteins (RAMPs).

CB1 / CB2 (Cannabinoid Receptors)

CB1 receptors are predominantly found in the central nervous system and modulate neurotransmitter release, appetite, pain perception, and mood. CB2 receptors are mainly expressed on immune cells and regulate inflammatory responses and immune cell migration. Both are GPCRs that respond to endocannabinoids such as anandamide and 2-AG, as well as phytocannabinoids.

CCK-A / CCK-B (Cholecystokinin Receptors)

CCK-A (now called CCK1) receptors are expressed primarily in the gastrointestinal tract and mediate satiety signaling, gallbladder contraction, and pancreatic enzyme secretion. CCK-B (CCK2) receptors are found in the brain and stomach, where they regulate anxiety-related behaviors and gastric acid secretion. Both are GPCRs activated by cholecystokinin peptides.

CGRP Receptor

The canonical calcitonin gene-related peptide receptor contains the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1), with additional intracellular coupling proteins. CGRP signaling participates in vasodilation and migraine biology. Approved monoclonal antibodies and small-molecule antagonists target the CGRP ligand or receptor for specific migraine indications.

CXCR4

A chemokine receptor belonging to the GPCR family that binds stromal cell-derived factor 1 (SDF-1/CXCL12). CXCR4 plays critical roles in stem cell homing, immune cell trafficking, and embryonic development. It is also a co-receptor for HIV entry into T-cells and is overexpressed in many cancers, making it a target for anti-metastatic therapies.

EGF Receptor (EGFR)

The epidermal growth factor receptor is a receptor tyrosine kinase that binds EGF and related growth factors. Activation triggers cell proliferation, survival, and differentiation pathways including MAPK/ERK and PI3K/AKT. EGFR mutations and overexpression are common in cancers, and multiple targeted therapies (gefitinib, erlotinib, cetuximab) have been developed against it.

FGF Receptor (FGFR)

Fibroblast growth factor receptors are a family of four receptor tyrosine kinases (FGFR1-4) that bind FGF ligands. They regulate cell growth, differentiation, angiogenesis, and wound healing. FGF signaling is critical in tissue repair and regeneration, and dysregulation is implicated in skeletal disorders and various cancers.

GHS-R (Ghrelin Receptor)

The growth hormone secretagogue receptor is a GPCR expressed in the hypothalamus, pituitary, and other tissues. Ghrelin is an endogenous ligand involved in growth-hormone release, appetite, and energy homeostasis. Experimental secretagogues such as GHRP-6 and hexarelin can activate this receptor, but receptor activity does not establish an approved indication.

GHRH-R (Growth Hormone Releasing Hormone Receptor)

A GPCR expressed on anterior pituitary somatotroph cells that binds GHRH and signals through pathways including cAMP/PKA to regulate growth-hormone synthesis and secretion. Sermorelin, tesamorelin, and CJC-1295 are GHRH-pathway analogues with different evidence and regulatory histories; class membership does not make them interchangeable.

GLP-1R (Glucagon-Like Peptide-1 Receptor)

A GPCR expressed in pancreatic beta cells and multiple other tissues. Activation by GLP-1 or medicines such as semaglutide and liraglutide can enhance glucose-dependent insulin secretion, reduce glucagon secretion, slow gastric emptying, and affect appetite. Tirzepatide activates both GIP and GLP-1 receptors and is classified as a dual agonist. Indications and contraindications are product-specific.

GnRH-R (Gonadotropin-Releasing Hormone Receptor)

A GPCR on anterior pituitary gonadotroph cells that binds GnRH to regulate the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Pulsatile GnRH stimulation maintains reproductive function, while continuous stimulation causes receptor desensitization and suppression of the HPG axis. GnRH agonists and antagonists are used in fertility treatment and hormone-sensitive cancers.

IGF-1R (Insulin-Like Growth Factor 1 Receptor)

A receptor tyrosine kinase that binds IGF-1 and IGF-2, activating PI3K/AKT and MAPK pathways to promote cell growth, survival, and differentiation. It plays a central role in the GH/IGF-1 axis and is critical for normal growth and development. IGF-1R signaling has been implicated in cancer progression and has been explored as a therapeutic target.

Integrin Receptors

A large family of heterodimeric transmembrane receptors composed of alpha and beta subunits that mediate cell adhesion to the extracellular matrix. Integrins transduce mechanical and chemical signals bidirectionally across the cell membrane, regulating cell migration, proliferation, and survival. They are critical in wound healing, angiogenesis, and immune cell trafficking, and several peptide motifs (such as RGD) target integrin binding.

MC1R (Melanocortin 1 Receptor)

A GPCR expressed on melanocytes that binds alpha-MSH and participates in melanin production and pigmentation. Afamelanotide is a synthetic alpha-MSH analogue with a specific approved indication; it should not be treated as interchangeable with unapproved products marketed under “melanotan” names. MC1R variants are associated with pigmentation phenotypes and differences in skin-cancer susceptibility.

MC3R (Melanocortin 3 Receptor)

A GPCR expressed in the hypothalamus, gut, and immune cells that participates in energy homeostasis and inflammation. MC3R modulates feeding behavior, fat storage, and circadian rhythms. Unlike MC4R, its role appears more related to energy partitioning (fat vs. lean mass) and peripheral immune regulation.

MC4R (Melanocortin 4 Receptor)

A GPCR in the hypothalamus that is a central regulator of appetite and energy balance. Activation by alpha-MSH or synthetic agonists like setmelanotide suppresses appetite, while loss-of-function mutations are the most common monogenic cause of obesity. MC4R is also the receptor through which melanotan II and PT-141 (bremelanotide) exert effects on sexual function.

mTOR (Mechanistic Target of Rapamycin)

A serine/threonine kinase that integrates nutrient availability, growth-factor signaling, and cellular energy status. mTOR functions in two major complexes: mTORC1 and mTORC2, which have overlapping but distinct substrates and roles. Rapamycin inhibits mTOR signaling and is studied in aging biology, but “geroprotective” effects in models do not establish a general anti-aging indication in people.

NK1R (Neurokinin 1 Receptor)

A GPCR that binds substance P, a neuropeptide involved in pain transmission, inflammation, and emesis. NK1R is expressed in the CNS and peripheral tissues and mediates neurogenic inflammation and nociceptive signaling. Antagonists like aprepitant are used clinically as antiemetics for chemotherapy-induced nausea.

NMDA Receptor

The N-methyl-D-aspartate receptor is a ligand-gated ion channel that requires both glutamate and glycine (or D-serine) for activation. It plays a central role in synaptic plasticity, learning, and memory through its calcium permeability. NMDA receptor dysfunction is implicated in neurodegeneration, chronic pain, and psychiatric disorders, and the receptor is modulated by various peptides and small molecules.

Notch Receptor

A single-pass transmembrane receptor that mediates cell-cell communication through direct contact with Notch ligands (Delta, Jagged) on adjacent cells. Upon activation, the intracellular domain is cleaved and translocates to the nucleus to regulate gene expression. Notch signaling controls cell fate decisions, stem cell maintenance, and tissue homeostasis, with dysregulation linked to cancer and developmental disorders.

Opioid Receptors (Mu, Delta, Kappa)

Three major classes of GPCRs that bind endogenous opioid peptides (endorphins, enkephalins, dynorphins) and exogenous opioid drugs. Mu receptors primarily mediate analgesia and euphoria, delta receptors modulate mood and pain, and kappa receptors are involved in dysphoria and stress responses. Understanding opioid receptor selectivity is essential for developing analgesic peptides with reduced side effects.

PPAR-gamma (Peroxisome Proliferator-Activated Receptor Gamma)

A nuclear receptor and transcription factor that regulates fatty acid storage, glucose metabolism, and adipocyte differentiation. PPAR-gamma activation promotes insulin sensitivity and is the target of thiazolidinedione drugs used in type 2 diabetes. It also modulates inflammation and has been studied in the context of metabolic syndrome and neurodegenerative disease.

Smoothened Receptor

A GPCR-like protein in the Hedgehog signaling pathway that is normally repressed by the Patched receptor. When Hedgehog ligand binds Patched, Smoothened is derepressed and activates Gli transcription factors. This pathway is critical in embryonic development, tissue patterning, and stem cell maintenance, with aberrant activation driving certain cancers (basal cell carcinoma, medulloblastoma).

TGF-beta Receptor

Transforming growth factor-beta receptors are serine/threonine kinases that form heteromeric complexes (Type I and Type II) upon TGF-beta ligand binding. They activate SMAD-dependent and SMAD-independent signaling to regulate cell growth, differentiation, apoptosis, and extracellular matrix production. TGF-beta signaling is central to wound healing and fibrosis, with context-dependent roles in cancer.

TLR2 / TLR4 (Toll-Like Receptors)

Pattern recognition receptors of the innate immune system that detect conserved microbial components. TLR4 recognizes lipopolysaccharide (LPS) from gram-negative bacteria, while TLR2 detects lipoproteins and peptidoglycan from gram-positive bacteria. Activation triggers NF-kappaB and inflammatory cytokine production, connecting innate immunity to adaptive immune responses.

VEGFR2 (Vascular Endothelial Growth Factor Receptor 2)

The primary signaling receptor for VEGF-A, a key driver of angiogenesis. VEGFR2 is a receptor tyrosine kinase expressed on vascular endothelial cells that promotes endothelial cell proliferation, migration, and vessel formation. It is a major therapeutic target in cancer (bevacizumab, ramucirumab) and retinal vascular diseases.

Wnt Receptor (Frizzled)

Frizzled receptors are a family of GPCRs that bind Wnt ligands in cooperation with LRP5/6 co-receptors. Activation initiates the canonical Wnt/beta-catenin pathway, which regulates cell proliferation, stem cell self-renewal, and tissue development. Dysregulated Wnt signaling is implicated in colorectal cancer, bone disorders, and degenerative diseases.

Y1 / Y2 / Y5 Receptors (Neuropeptide Y Receptors)

GPCRs that bind neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP). Y1 receptors stimulate appetite and are involved in anxiety and vasoconstriction. Y2 receptors mediate feedback inhibition of NPY release and are targets for appetite suppression research. Y5 receptors also participate in feeding behavior and energy homeostasis.

---

Signaling Pathways

AMPK Pathway

AMP-activated protein kinase is a cellular energy sensor activated when the AMP:ATP ratio rises during metabolic stress. AMPK promotes catabolic processes (fatty acid oxidation, glucose uptake, autophagy) while inhibiting anabolic processes (protein synthesis via mTORC1 inhibition, lipogenesis). It is a key target in metabolic disease research and is activated by metformin and exercise.

Autophagy (ATG) Pathway

A conserved cellular recycling process in which damaged organelles and misfolded proteins are enclosed in autophagosomes and delivered to lysosomes for degradation. Regulated by ATG (autophagy-related) genes, this pathway maintains cellular homeostasis and is induced by nutrient deprivation, mTORC1 inhibition, and AMPK activation. Dysfunctional autophagy is linked to neurodegeneration, cancer, and aging.

Calcineurin/NFAT Pathway

Calcineurin is a calcium-dependent phosphatase that dephosphorylates NFAT (Nuclear Factor of Activated T-cells), allowing its nuclear translocation and transcriptional activation. This pathway is essential for T-cell activation and immune responses, cardiac hypertrophy, and skeletal muscle fiber-type specification. Immunosuppressants cyclosporine and tacrolimus work by inhibiting calcineurin.

cAMP/PKA Pathway

Cyclic adenosine monophosphate (cAMP) is a second messenger generated by adenylyl cyclase upon GPCR activation. cAMP activates protein kinase A (PKA), which phosphorylates downstream targets including CREB transcription factor. This pathway mediates the actions of many peptide hormones including GHRH, GLP-1, and ACTH, regulating metabolism, gene expression, and hormone secretion.

CREB Signaling

cAMP response element-binding protein is a transcription factor activated by phosphorylation, primarily through PKA but also by MAPK and calcium-dependent kinases. Phosphorylated CREB binds CRE (cAMP response element) sequences in gene promoters to regulate genes involved in neuronal survival, memory consolidation, gluconeogenesis, and neuropeptide expression.

FAK/Paxillin Pathway

Focal adhesion kinase (FAK) is a tyrosine kinase recruited to integrin-mediated focal adhesions upon cell-matrix binding. FAK phosphorylates paxillin and other scaffold proteins to regulate cell migration, survival, and mechanotransduction. This pathway is critical in wound healing, tissue remodeling, and is often hyperactivated in metastatic cancers.

Ferroptosis Pathway

A regulated form of cell death driven by iron-dependent lipid peroxidation, distinct from apoptosis and necrosis. Ferroptosis occurs when glutathione peroxidase 4 (GPX4) activity is insufficient to neutralize lipid hydroperoxides. This pathway has gained attention in cancer therapy (inducing ferroptosis in resistant tumors) and neurodegeneration (protecting neurons from ferroptotic damage).

Hedgehog Pathway

A developmental signaling cascade initiated when Hedgehog ligands (Sonic, Indian, or Desert) bind the Patched receptor, relieving inhibition of Smoothened. Downstream Gli transcription factors then regulate target genes controlling cell proliferation, differentiation, and patterning. Aberrant Hedgehog signaling drives certain cancers, and the pathway is involved in tissue repair and stem cell maintenance.

Hippo/YAP Pathway

A kinase cascade (MST1/2 and LATS1/2) that phosphorylates and inactivates YAP/TAZ transcriptional co-activators, restricting organ growth and promoting apoptosis. When the Hippo pathway is inactive, unphosphorylated YAP enters the nucleus and drives proliferation and survival gene expression. This pathway regulates organ size, stem cell self-renewal, and tissue regeneration, with dysregulation implicated in cancer.

Inflammasome (NLRP3)

A multiprotein complex that assembles in response to danger signals (pathogen-associated and damage-associated molecular patterns) to activate caspase-1. Active caspase-1 cleaves pro-IL-1beta and pro-IL-18 into their mature inflammatory forms and can trigger pyroptosis. NLRP3 inflammasome activation is implicated in gout, atherosclerosis, Alzheimer's disease, and metabolic syndrome.

JAK/STAT Pathway

Janus kinase/signal transducer and activator of transcription is a signaling cascade activated by cytokines, interferons, and growth factors. Ligand binding to cytokine receptors activates JAK kinases, which phosphorylate STAT proteins. Phosphorylated STATs dimerize and translocate to the nucleus to regulate immune function, hematopoiesis, and cell growth. JAK inhibitors (tofacitinib, ruxolitinib) are used in autoimmune and myeloproliferative diseases.

JNK Pathway

c-Jun N-terminal kinases are stress-activated protein kinases in the MAPK superfamily that respond to UV radiation, inflammatory cytokines, and oxidative stress. JNK phosphorylates c-Jun and other transcription factors to regulate apoptosis, inflammation, and cell differentiation. Chronic JNK activation is implicated in insulin resistance, neurodegeneration, and liver disease.

MAPK/ERK Pathway

The mitogen-activated protein kinase/extracellular signal-regulated kinase cascade (Ras-Raf-MEK-ERK) is one of the most studied signaling pathways in cell biology. Activated by growth factors binding receptor tyrosine kinases, it drives cell proliferation, differentiation, and survival. Dysregulation through oncogenic Ras or Raf mutations is found in many cancers, making pathway components key therapeutic targets.

mTORC1 / mTORC2

Two distinct multiprotein complexes formed by the mTOR kinase. mTORC1 (with Raptor) integrates nutrient, energy, and growth factor signals to regulate protein synthesis through S6K and 4E-BP1 phosphorylation, and is sensitive to rapamycin. mTORC2 (with Rictor) regulates cell survival via AKT phosphorylation and cytoskeletal organization, and is relatively rapamycin-insensitive in acute treatment.

NF-kappaB Pathway

Nuclear factor kappa-light-chain-enhancer of activated B cells is a family of transcription factors that regulate inflammation, immunity, cell survival, and proliferation. In the canonical pathway, inflammatory signals activate IKK, which phosphorylates IkappaB for degradation, releasing NF-kappaB to enter the nucleus. Chronic NF-kappaB activation is a hallmark of inflammatory diseases and many cancers.

NO/cGMP Pathway

Nitric oxide synthase (NOS) produces nitric oxide (NO), which diffuses into target cells and activates soluble guanylyl cyclase to produce cyclic GMP (cGMP). cGMP activates protein kinase G (PKG), leading to smooth muscle relaxation and vasodilation. This pathway is critical in cardiovascular function, neurotransmission, and penile erection, and is targeted by phosphodiesterase-5 inhibitors like sildenafil.

Notch Signaling

Cell-contact-dependent signaling initiated when Notch receptors on one cell interact with Delta or Jagged ligands on an adjacent cell. Proteolytic cleavage releases the Notch intracellular domain (NICD), which enters the nucleus to activate transcription of HES and HEY genes. This pathway controls binary cell fate decisions, stem cell maintenance, and is frequently mutated in T-cell acute lymphoblastic leukemia.

Nrf2/ARE Pathway

Nuclear factor erythroid 2-related factor 2 is a transcription factor that, under oxidative stress, dissociates from its inhibitor Keap1 and translocates to the nucleus. There it binds antioxidant response elements (ARE) to upregulate detoxification enzymes (glutathione S-transferase, heme oxygenase-1, NAD(P)H quinone oxidoreductase). This pathway is the master regulator of cellular antioxidant defense and is studied in neuroprotection and aging.

p53 Pathway

The tumor suppressor p53, called the "guardian of the genome," is activated by DNA damage, oncogene activation, and other stress signals. It induces cell cycle arrest, DNA repair, senescence, or apoptosis depending on the severity of damage. p53 is mutated or inactivated in approximately half of all human cancers, making it one of the most important proteins in cancer biology.

PI3K/AKT Pathway

Phosphoinositide 3-kinase generates PIP3 at the cell membrane, recruiting and activating the serine/threonine kinase AKT (protein kinase B). AKT promotes cell survival (inhibiting pro-apoptotic factors), growth (activating mTORC1), and metabolism (enhancing glucose uptake). This pathway is frequently hyperactivated in cancer through PIK3CA mutations or PTEN loss.

PKC Pathway

Protein kinase C is a family of serine/threonine kinases activated by diacylglycerol (DAG) and calcium. PKC isoforms regulate diverse cellular processes including cell proliferation, apoptosis, migration, and immune cell activation. Different isoforms (conventional, novel, atypical) have distinct activation requirements and tissue distributions, making isoform-selective targeting an active area of drug development.

Proteasome Pathway

The ubiquitin-proteasome system is the primary mechanism for targeted protein degradation in eukaryotic cells. Proteins marked with polyubiquitin chains are recognized and degraded by the 26S proteasome. This pathway regulates cell cycle progression, transcription factor turnover, and immune antigen presentation. Proteasome inhibitors (bortezomib) are used in multiple myeloma treatment.

Src Kinase Pathway

Src is a non-receptor tyrosine kinase that integrates signals from multiple receptor types (integrins, GPCRs, receptor tyrosine kinases) to regulate cell adhesion, migration, and proliferation. It was the first proto-oncogene discovered and remains relevant in cancer biology. Src family kinases (SFKs) also play roles in bone remodeling, immune function, and neural development.

TGF-beta/SMAD Pathway

Transforming growth factor-beta signals through type I and type II serine/threonine kinase receptors, which phosphorylate receptor-regulated SMADs (SMAD2/3). These form complexes with SMAD4 and translocate to the nucleus to regulate transcription of genes controlling cell growth, differentiation, and extracellular matrix production. This pathway is central to fibrosis, wound healing, and has dual roles in cancer (tumor suppression early, promotion late).

Wnt/Beta-Catenin Pathway

In the canonical Wnt pathway, Wnt ligands bind Frizzled receptors and LRP5/6 co-receptors, inhibiting the beta-catenin destruction complex (APC, Axin, GSK-3beta). Stabilized beta-catenin accumulates and enters the nucleus to activate TCF/LEF target genes driving proliferation and stemness. This pathway is essential for intestinal stem cell maintenance, bone formation, and is constitutively active in most colorectal cancers through APC mutations.

---

Molecular Biology Terms

Actin

A globular protein (G-actin) that polymerizes into filamentous actin (F-actin), forming a major component of the cytoskeleton. Actin filaments provide mechanical support, drive cell motility and shape changes, and are essential for muscle contraction. Dynamic actin remodeling is regulated by numerous binding proteins and signaling pathways, including Rho GTPases.

Chaperone Protein

Molecular chaperones assist in the proper folding of newly synthesized proteins and prevent aggregation of misfolded proteins under stress conditions. They include heat shock proteins (HSP70, HSP90), chaperonins (GroEL/GroES, TRiC), and small heat shock proteins. Chaperone dysfunction contributes to protein aggregation diseases such as Alzheimer's and Parkinson's.

Chromatin Remodeling

The dynamic modification of chromatin architecture by ATP-dependent remodeling complexes (SWI/SNF, ISWI, CHD, INO80) that reposition or eject nucleosomes. This process regulates access of transcription factors and RNA polymerase to DNA, controlling gene expression without changing the DNA sequence. Mutations in chromatin remodeling factors are common in cancer.

Collagen

The most abundant protein in mammals, forming the primary structural component of connective tissues including skin, bone, tendon, and cartilage. Collagen molecules assemble into a triple-helix structure and further organize into fibrils and fibers. At least 28 types of collagen exist, with type I being most abundant. Peptides like GHK-Cu are studied for their ability to stimulate collagen synthesis.

DNA Methylation

An epigenetic modification in which a methyl group is added to cytosine bases, primarily at CpG dinucleotides, by DNA methyltransferases (DNMTs). Methylation of gene promoter regions typically represses transcription by preventing transcription factor binding or recruiting methyl-binding proteins. DNA methylation patterns change with age and are used in epigenetic clock calculations of biological age.

Elastin

A highly elastic structural protein found in connective tissues that allows organs like the lungs, arteries, and skin to stretch and recoil. Elastin is produced primarily during development by fibroblasts and smooth muscle cells and has very slow turnover in adults. Loss of elastin integrity contributes to wrinkle formation, arterial stiffness, and emphysema with aging.

Epigenetics

The study of heritable changes in gene expression that do not involve alterations to the DNA sequence itself. Major epigenetic mechanisms include DNA methylation, histone modifications, and non-coding RNA regulation. Epigenetic changes accumulate with age and environmental exposures, and epigenetic reprogramming is a frontier in longevity research.

Extracellular Matrix (ECM)

A complex network of proteins (collagen, elastin, fibronectin, laminin) and carbohydrates (glycosaminoglycans, proteoglycans) that provides structural and biochemical support to surrounding cells. The ECM regulates cell behavior through mechanical signaling and growth factor sequestration. ECM remodeling by matrix metalloproteinases (MMPs) is central to wound healing, fibrosis, and cancer metastasis.

Fibronectin

A high-molecular-weight glycoprotein that binds integrins and extracellular matrix components to mediate cell adhesion, migration, and differentiation. Fibronectin exists in soluble (plasma) and insoluble (tissue) forms and is critical for wound healing and embryonic development. It contains the RGD (Arg-Gly-Asp) motif that many synthetic peptides mimic for biomaterial applications.

Gene Promoter

A region of DNA upstream of a gene that contains binding sites for RNA polymerase and transcription factors to initiate transcription. Promoters include core elements (TATA box, initiator) and regulatory elements (enhancers, silencers) that determine when, where, and how much a gene is expressed. Epigenetic modifications at promoter regions are key regulators of gene activity.

Glycosaminoglycan (GAG)

Long unbranched polysaccharides consisting of repeating disaccharide units, found on cell surfaces and in the extracellular matrix. Major GAGs include hyaluronic acid, heparan sulfate, chondroitin sulfate, and keratan sulfate. They bind water to provide tissue hydration and cushioning, and interact with growth factors and cytokines to modulate signaling.

Heat Shock Protein (HSP)

A family of molecular chaperones upregulated in response to heat, oxidative stress, and other cellular insults. HSP70 and HSP90 are among the best characterized, assisting in protein folding, preventing aggregation, and targeting damaged proteins for degradation. HSPs are being studied in the context of aging, neurodegeneration, and cancer immunotherapy.

Histone Acetylation

The addition of acetyl groups to lysine residues on histone proteins by histone acetyltransferases (HATs). Acetylation neutralizes the positive charge of histones, relaxing chromatin structure and promoting gene transcription. Histone deacetylases (HDACs) remove acetyl groups to repress gene expression. HDAC inhibitors are used in cancer therapy and are being studied in aging research.

hTERT (Human Telomerase Reverse Transcriptase)

The catalytic subunit of the enzyme telomerase, which adds TTAGGG repeat sequences to chromosome ends to counteract telomere shortening. Most somatic cells have low or absent hTERT expression, leading to progressive telomere attrition with each cell division. Reactivation of hTERT is a hallmark of cancer cells and a target in longevity research; the peptide epitalon is studied for its potential to activate telomerase.

Laminin

A major glycoprotein component of basement membranes that mediates cell adhesion, migration, and differentiation through integrin and non-integrin receptors. Laminins are heterotrimeric proteins composed of alpha, beta, and gamma chains, forming at least 16 known isoforms. They are essential for tissue architecture and play critical roles in neural development and muscle function.

mRNA (Messenger RNA)

A single-stranded RNA molecule transcribed from DNA that carries the genetic code to ribosomes for protein synthesis. mRNA is processed through 5' capping, splicing, and 3' polyadenylation before translation. mRNA technology gained prominence through COVID-19 vaccines and is being explored for peptide and protein therapeutic delivery.

Proteasome

A large protein complex (26S) that degrades ubiquitin-tagged proteins into small peptides, serving as the cell's primary protein disposal system. The 20S catalytic core cleaves peptide bonds, while 19S regulatory caps recognize ubiquitinated substrates. Proteasome function declines with age, contributing to the accumulation of damaged proteins and loss of proteostasis.

Proteoglycan

Heavily glycosylated proteins consisting of a core protein with one or more covalently attached glycosaminoglycan chains. Found on cell surfaces and in the extracellular matrix, proteoglycans regulate growth factor signaling, tissue hydration, and structural integrity. Examples include aggrecan (cartilage), syndecan, and perlecan (basement membranes).

Ribosome

A large macromolecular complex composed of ribosomal RNA and proteins that catalyzes protein synthesis (translation) by reading mRNA codons and assembling amino acid chains. Eukaryotic ribosomes (80S) consist of 40S and 60S subunits. Ribosome biogenesis is tightly regulated by mTORC1, connecting nutrient sensing to translational capacity.

siRNA (Small Interfering RNA)

Short double-stranded RNA molecules (20-25 nucleotides) that silence gene expression through the RNA interference (RNAi) pathway. siRNA guides the RISC complex to complementary mRNA sequences for degradation, preventing protein translation. siRNA therapeutics (patisiran) have been approved for clinical use and represent a tool for studying peptide-related gene function.

Telomerase

A ribonucleoprotein enzyme complex that extends telomeres by adding TTAGGG repeats using its RNA template component (TERC) and catalytic subunit (hTERT). Active in stem cells, germ cells, and most cancer cells, telomerase counteracts the end-replication problem. Research peptides like epitalon are investigated for their potential to modulate telomerase activity and influence cellular aging.

Telomere

Repetitive TTAGGG nucleotide sequences at chromosome ends that protect genomic DNA from degradation and fusion during cell division. Telomeres shorten with each replication cycle due to the end-replication problem, and critically short telomeres trigger cellular senescence or apoptosis. Telomere length is considered a biomarker of biological aging and is influenced by lifestyle factors and certain peptides.

Transcription Factor

A protein that binds specific DNA sequences to regulate gene transcription by promoting or blocking RNA polymerase recruitment. Transcription factors can be activated by phosphorylation, ligand binding, or proteolytic processing, and often function as dimers or larger complexes. Examples relevant to peptide biology include CREB, NF-kappaB, p53, and STAT proteins.

Tubulin

A globular protein that polymerizes into microtubules, cylindrical structures that form the mitotic spindle, provide intracellular transport tracks, and maintain cell shape. Alpha and beta tubulin heterodimers assemble dynamically, and microtubule-targeting drugs (taxanes, vinca alkaloids) are major chemotherapeutics. Tubulin post-translational modifications regulate microtubule stability and motor protein binding.

Ubiquitin

A small 76-amino-acid protein that is covalently attached to target proteins through an enzymatic cascade (E1, E2, E3 ligases) to mark them for proteasomal degradation, alter their activity, or change their localization. Polyubiquitin chains linked through different lysine residues encode distinct signals. The ubiquitin system regulates virtually all cellular processes and its dysfunction contributes to neurodegeneration and cancer.

---

Cell Biology

Apoptosis

Programmed cell death executed through intrinsic (mitochondrial) or extrinsic (death receptor) pathways, resulting in orderly cellular dismantlement without inflammation. Characterized by caspase activation, DNA fragmentation, cell shrinkage, and membrane blebbing. Apoptosis is essential for development and tissue homeostasis, and its dysregulation contributes to cancer (insufficient apoptosis) or neurodegeneration (excessive apoptosis).

Autophagy

A conserved cellular self-digestion process in which cytoplasmic components and damaged organelles are sequestered in double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. Autophagy maintains cellular homeostasis, is induced by fasting and caloric restriction, and declines with age. Enhancing autophagy is a strategy explored in longevity research.

B-cell

Lymphocytes of the adaptive immune system that mature in bone marrow and produce antibodies (immunoglobulins) upon antigen activation. B-cells can differentiate into plasma cells (antibody factories) or memory B-cells (long-term immunity). They also function as antigen-presenting cells and are central to vaccine-induced and natural humoral immunity.

Chondrocyte

The only cell type found in healthy cartilage, responsible for producing and maintaining the cartilaginous matrix of collagen and proteoglycans. Chondrocytes reside in low-oxygen environments and have limited regenerative capacity. Peptides like BPC-157 and growth factors are studied for their potential to support chondrocyte function and cartilage repair.

Dendritic Cell

Professional antigen-presenting cells that serve as the bridge between innate and adaptive immunity. Dendritic cells capture antigens in peripheral tissues, process them, and migrate to lymph nodes where they present peptide-MHC complexes to T-cells, initiating adaptive immune responses. They are central to vaccine development and cancer immunotherapy.

Endothelial Cell

Cells that line the interior surface of blood vessels and lymphatic vessels, forming the endothelium. They regulate vascular tone, permeability, angiogenesis, coagulation, and immune cell trafficking. Endothelial dysfunction is a key early event in atherosclerosis, and VEGF signaling through endothelial cells drives new blood vessel formation.

Fibroblast

A connective-tissue cell involved in producing and remodeling extracellular-matrix components including collagen and fibronectin. During wound healing, some fibroblasts acquire a contractile myofibroblast phenotype. Fibroblast assays are often used in GHK-Cu research, but changes in cell culture do not establish a clinical anti-aging effect.

Keratinocyte

The predominant cell type in the epidermis (outermost skin layer), responsible for producing keratin and forming the protective skin barrier. Keratinocytes originate in the basal layer and differentiate as they migrate upward, eventually forming the cornified (dead) layer. They also produce antimicrobial peptides and cytokines, contributing to skin immune defense.

Macrophage

Innate immune cells derived from monocytes that phagocytose pathogens, dead cells, and debris. Macrophages exist on a spectrum between M1 (pro-inflammatory, antimicrobial) and M2 (anti-inflammatory, tissue repair) polarization states. They play critical roles in wound healing, host defense, and chronic inflammation, and are influenced by various peptide signals including thymosin beta-4.

Mast Cell

Tissue-resident immune cells packed with granules containing histamine, heparin, proteases, and cytokines. Upon activation (classically through IgE cross-linking), mast cells degranulate and release inflammatory mediators that drive allergic reactions, anaphylaxis, and host defense against parasites. They also participate in wound healing and tissue remodeling.

Meiosis

A specialized form of cell division that produces four haploid gametes (eggs or sperm) from a single diploid cell, involving two sequential divisions and genetic recombination through crossing over. Meiosis ensures genetic diversity and proper chromosome number in sexually reproducing organisms. Errors in meiosis lead to aneuploidy and conditions such as Down syndrome.

Mitosis

The process of nuclear division in eukaryotic cells that produces two genetically identical daughter cells. It consists of prophase, metaphase, anaphase, and telophase, followed by cytokinesis. Mitosis is tightly regulated by cyclin-CDK complexes and checkpoints that ensure accurate chromosome segregation, with dysregulation leading to cancer.

NK Cell (Natural Killer Cell)

Innate lymphocytes that provide rapid immune responses against virus-infected and tumor cells without prior sensitization. NK cells recognize stressed cells through a balance of activating and inhibitory receptors and kill targets through perforin/granzyme pathways or death receptor interactions. They are being harnessed in cancer immunotherapy and are modulated by various peptide factors including thymosin alpha-1.

Osteoblast

Bone-forming cells derived from mesenchymal stem cells that synthesize and mineralize the bone matrix (osteoid). Osteoblasts produce type I collagen, osteocalcin, and alkaline phosphatase, and respond to growth factors, hormones (PTH, estrogen), and mechanical loading. Some osteoblasts become embedded in bone matrix as osteocytes, which act as mechanosensors.

Osteoclast

Large multinucleated cells derived from monocyte/macrophage precursors that resorb bone by secreting acid and proteolytic enzymes (cathepsin K) into a sealed resorption lacuna. Osteoclast activity is regulated by RANKL/OPG balance and is inhibited by calcitonin. Excessive osteoclast activity leads to osteoporosis, while insufficient activity causes osteopetrosis.

Progenitor Cell

A partially differentiated cell with limited self-renewal capacity that is committed to producing one or a few specific cell types. Unlike stem cells, progenitor cells are more restricted in their differentiation potential. Examples include satellite cells (muscle progenitors), transit-amplifying cells in the gut, and neural progenitor cells in the brain.

Satellite Cell

Muscle-resident stem/progenitor cells located between the sarcolemma and basal lamina of muscle fibers. Normally quiescent, satellite cells are activated by muscle injury or exercise to proliferate, differentiate, and fuse with existing muscle fibers or form new ones. They are essential for muscle regeneration and are influenced by growth factors including IGF-1 and HGF.

Senescence

A state of permanent cell cycle arrest triggered by telomere shortening, DNA damage, oncogene activation, or oxidative stress. Senescent cells remain metabolically active and secrete the senescence-associated secretory phenotype (SASP), a cocktail of pro-inflammatory cytokines, proteases, and growth factors. Accumulation of senescent cells with age contributes to tissue dysfunction and chronic inflammation.

Stem Cell

An undifferentiated cell capable of self-renewal and differentiation into specialized cell types. Embryonic stem cells are pluripotent (can form any cell type), while adult stem cells are typically multipotent (limited lineage potential). Stem cell exhaustion is a hallmark of aging, and maintaining stem cell pools through peptide and growth factor signaling is an active research area.

T-cell

Lymphocytes that mature in the thymus and mediate cellular adaptive immunity. Major subtypes include CD4+ helper T-cells (coordinate immune responses), CD8+ cytotoxic T-cells (kill infected/tumor cells), and regulatory T-cells (suppress immune responses). T-cell function declines with age (immunosenescence) and can be modulated by thymic peptides like thymosin alpha-1 and thymulin.

---

Pharmacology

Agonist

A substance that binds to and activates a receptor, mimicking the effect of the natural ligand. Full agonists produce maximal receptor activation, while partial agonists produce submaximal responses even at full receptor occupancy. Many therapeutic peptides function as receptor agonists, such as GLP-1 receptor agonists (semaglutide) and GHRH agonists (sermorelin).

Allosteric Modulator

A substance that binds a receptor at a site distinct from the orthosteric (primary ligand) binding site, altering the receptor's response to its natural ligand. Positive allosteric modulators (PAMs) enhance receptor activity, while negative allosteric modulators (NAMs) reduce it. Allosteric modulation offers advantages of preserved physiological signaling patterns and reduced receptor desensitization.

Antagonist

A substance that binds to a receptor without activating it, blocking the binding and effect of agonists. Competitive antagonists compete for the same binding site as the agonist, while non-competitive antagonists bind elsewhere. Examples include GnRH antagonists (degarelix) and CGRP receptor antagonists (rimegepant) used in migraine treatment.

Bioavailability

The fraction of an administered dose that reaches systemic circulation unchanged. Intravenous administration is treated as 100% bioavailable by definition. Oral bioavailability varies by molecule and formulation; many peptides face enzymatic degradation and limited intestinal permeability. See the bioavailability guide.

Biologic

A regulatory and scientific umbrella for products such as vaccines, blood components, recombinant proteins, monoclonal antibodies, and some other products derived through biological processes. “Biologic” is not simply a synonym for every peptide: regulatory classification can depend on product type and governing law. Route and storage requirements are product-specific.

Blood-Brain Barrier (BBB)

A highly selective semipermeable border of endothelial cells linked by tight junctions that separates the circulating blood from the brain extracellular fluid. The BBB restricts passage of most molecules, protecting the brain but also limiting drug delivery. Strategies to cross the BBB include receptor-mediated transcytosis, cell-penetrating peptides, and focused ultrasound.

Clearance

The volume of plasma from which a drug is completely removed per unit time, a key pharmacokinetic parameter reflecting the body's efficiency at eliminating a substance. Renal clearance and hepatic clearance are the two major routes. Peptides are often rapidly cleared by renal filtration and enzymatic degradation, necessitating modifications (PEGylation, lipidation, Fc fusion) to extend their duration of action.

EC50

The effective concentration of a drug that produces 50% of its maximal effect, a measure of potency. A lower EC50 indicates higher potency. EC50 is determined from dose-response curves and is used to compare the potencies of different agonists at the same receptor or the same drug at different targets.

First-Pass Metabolism

The metabolism of an orally administered drug by gastrointestinal and hepatic enzymes before it reaches systemic circulation. Peptides are particularly susceptible to first-pass degradation by proteases in the gut and liver. This is a primary reason oral peptide delivery is challenging and why technologies like SNAC (used with oral semaglutide) and enteric coatings are being developed.

Half-Life

The time required for the plasma concentration of a drug to decrease by 50%. Peptide half-lives range from minutes (most native peptides) to days or weeks (PEGylated or lipidated analogs). Understanding half-life is essential for determining dosing frequency and achieving consistent therapeutic levels.

IC50

The inhibitory concentration of a substance that reduces a biological process by 50%, commonly used to measure the potency of enzyme inhibitors or receptor antagonists. A lower IC50 indicates greater inhibitory potency. IC50 values are context-dependent and can vary with assay conditions, substrate concentrations, and incubation times.

Loading Dose

An initial dose intended to reach a target concentration more quickly than repeated maintenance dosing alone. Whether a loading dose is appropriate depends on a validated product-specific regimen, distribution, clearance, therapeutic window, and clinical setting; the term does not justify creating an improvised protocol.

Pharmacodynamics (PD)

The study of what a drug does to the body: its biochemical and physiological effects, mechanisms of action, and the relationship between drug concentration and effect. For peptides, pharmacodynamics encompasses receptor binding, signaling pathway activation, and downstream biological responses such as hormone release, gene expression changes, and tissue effects.

Pharmacokinetics (PK)

The study of what the body does to a drug: its absorption, distribution, metabolism, and excretion (ADME). Peptide pharmacokinetics present unique challenges including rapid proteolytic degradation, poor oral absorption, short plasma half-lives, and limited tissue distribution. Chemical modifications and advanced delivery systems aim to improve peptide PK profiles.

Prodrug

An inactive or less active compound that is converted to its active form by enzymatic or chemical processes in the body. Prodrug strategies for peptides include ester prodrugs for improved oral absorption, protease-activated prodrugs for targeted delivery, and depot formulations that slowly release active peptide at the injection site.

Receptor Desensitization

A reduction in receptor responsiveness following prolonged or repeated agonist exposure. Mechanisms include receptor phosphorylation, beta-arrestin recruitment, receptor internalization, and downregulation of receptor expression. Desensitization is clinically relevant for peptide hormones: continuous GnRH exposure causes pituitary desensitization, while pulsatile delivery maintains receptor sensitivity.

Steady State

The condition in which the rate of drug administration equals the rate of elimination, resulting in a stable plasma concentration over time. Steady state is typically achieved after 4-5 half-lives of repeated dosing. For peptides with modified half-lives (like once-weekly semaglutide), reaching steady state may take several weeks.

Tachyphylaxis

A rapid decrease in response after repeated exposure, occurring more quickly than typical tolerance. Proposed mechanisms include receptor desensitization or depletion of a mediator. Demonstrating tachyphylaxis requires repeated-response data; it cannot be inferred from a compound’s receptor class alone.

Therapeutic Index

A comparison between doses or exposures associated with desired and toxic effects, often summarized as TD50/ED50 in simplified teaching examples. A wider separation can suggest a larger safety margin, but real benefit-risk assessment also considers the severity, frequency, and reversibility of harms. Peptides do not inherently have a favorable therapeutic index.

Volume of Distribution (Vd)

A pharmacokinetic parameter that relates the total amount of drug in the body to its plasma concentration. A large Vd indicates extensive tissue distribution, while a small Vd suggests the drug remains mainly in the plasma. Most peptides have small volumes of distribution due to their hydrophilicity and large molecular size, limiting their ability to penetrate tissues.

---

Peptide Chemistry

Acetylation

The addition of an acetyl group (CH3CO) to a molecule, commonly at the N-terminus of peptides. N-terminal acetylation protects peptides from aminopeptidase degradation, increasing metabolic stability and half-life. It can also influence receptor binding affinity and peptide folding. Many synthetic research peptides are acetylated to improve their pharmacokinetic properties.

Alpha Helix

A common secondary structure in proteins and peptides in which the polypeptide chain coils into a right-handed helical shape stabilized by hydrogen bonds between the backbone carbonyl of residue i and the amide NH of residue i+4. Alpha helices are found in many biologically active peptides and are important for receptor interaction. Stapled peptides use chemical crosslinks to stabilize alpha-helical structure.

Amidation

The modification of a peptide's C-terminus from a free carboxyl group (-COOH) to an amide group (-CONH2). C-terminal amidation is a common post-translational modification in bioactive peptides (over half of known neuropeptides are amidated). It protects against carboxypeptidase degradation and often enhances receptor binding affinity and biological activity.

Amino Acid

The building blocks of peptides and proteins, consisting of an amino group, a carboxyl group, a hydrogen atom, and a distinctive side chain (R group) bonded to a central carbon atom. Twenty standard amino acids are encoded by DNA, each with unique chemical properties. Non-standard and synthetic amino acids are used in peptide chemistry to improve stability, potency, or selectivity.

Bacteriostatic Water

A sterile diluent containing a bacteriostatic preservative, commonly benzyl alcohol, in a labeled drug product. It is not universally appropriate for every molecule, route, patient, or container. Compatibility, beyond-use time, and handling must come from the applicable product labeling or qualified pharmacy procedure—not from a generic peptide glossary.

Beta Sheet

A secondary protein structure formed when two or more polypeptide strands align side-by-side and are connected by hydrogen bonds between backbone atoms. Beta sheets can be parallel or antiparallel and provide structural rigidity. Amyloid fibrils in neurodegenerative diseases are composed of cross-beta sheet structures, making beta-sheet-disrupting peptides a therapeutic strategy.

C-terminus

The end of a peptide or protein chain that has a free carboxyl group (-COOH), representing the last amino acid added during ribosomal synthesis. The C-terminus is a common site for post-translational modifications including amidation and GPI anchor attachment. Many peptide drugs are modified at the C-terminus to improve stability or activity.

Cyclization

The formation of a cyclic peptide structure through bonds between the N-terminus and C-terminus (head-to-tail), between side chains, or between a terminus and a side chain. Cyclization constrains peptide conformation, often increasing receptor selectivity, metabolic stability, and membrane permeability compared to linear counterparts. Examples include cyclosporine and many antimicrobial peptides.

Diluent

A liquid used to dissolve or dilute another material. Suitability depends on chemical compatibility, concentration, route, sterility requirements, container, and the validated method. Diluents are not interchangeable merely because a material dissolves visibly.

Disulfide Bond

A covalent bond formed between the sulfur atoms of two cysteine residues, either within a single peptide (intramolecular) or between separate chains (intermolecular). Disulfide bonds stabilize three-dimensional structure and are critical for the biological activity of peptides like insulin (two interchain and one intrachain disulfide bond) and oxytocin. They are formed in oxidizing environments such as the endoplasmic reticulum.

Fmoc Chemistry

Fluorenylmethyloxycarbonyl chemistry is the most widely used protecting group strategy in solid-phase peptide synthesis. The Fmoc group protects the alpha-amino group during chain assembly and is removed by piperidine under mild basic conditions, while side-chain protecting groups are removed by acid treatment after chain assembly. Fmoc SPPS allows synthesis of peptides up to about 50 amino acids.

HPLC (High-Performance Liquid Chromatography)

An analytical or preparative technique that separates mixture components through differential interactions with a stationary phase and mobile phase. Reversed-phase HPLC is commonly used for peptides. A main-peak area percentage is method-dependent and does not, by itself, prove identity, absolute content, sterility, or absence of co-eluting impurities. See the purity testing guide.

Lyophilization

Freeze-drying: a process in which a frozen formulation is placed under reduced pressure so ice is removed primarily by sublimation, followed by secondary drying. Lyophilization can improve stability when the formulation and cycle are validated, but a dry cake does not prove identity, purity, sterility, or an indefinite shelf life.

Mass Spectrometry (MS)

An analytical technique that measures mass-to-charge ratios of ions. MALDI-TOF, ESI-MS, and tandem MS can support molecular-mass, sequence, and modification assignments. A matching intact mass supports identity but does not alone establish purity, concentration, stereochemistry, sterility, or biological activity.

N-terminus

The end of a peptide or protein chain that has a free amino group (-NH2), representing the first amino acid incorporated during ribosomal synthesis. The N-terminus is susceptible to aminopeptidase degradation, which is why many synthetic peptides are acetylated at this position. N-terminal modifications can also influence receptor binding and biological activity.

PEGylation

The covalent attachment of polyethylene glycol (PEG) polymer chains to peptides or proteins. PEGylation increases hydrodynamic radius (reducing renal clearance), shields from proteolytic degradation, and reduces immunogenicity. This modification extends the circulating half-life of peptide therapeutics, allowing less frequent dosing. Examples include PEGylated interferons and growth hormone formulations.

Peptide Bond

The covalent amide bond formed between the carboxyl group of one amino acid and the amino group of another, with the release of water (condensation reaction). Peptide bonds have partial double-bond character due to resonance, making them planar and relatively rigid. They are the fundamental linkages that join amino acids in peptides and proteins.

Post-Translational Modification (PTM)

Chemical modifications made to a protein or peptide after its ribosomal synthesis. Common PTMs include phosphorylation, glycosylation, acetylation, amidation, methylation, ubiquitination, and disulfide bond formation. PTMs regulate protein function, localization, stability, and interactions, and are crucial for the biological activity of many endogenous peptides.

Reconstitution

The process of adding a specified diluent to a dry formulation to produce a solution or suspension. The correct diluent, volume, technique, storage conditions, and beyond-use time are formulation-specific. Visible dissolution is not evidence that the resulting material is suitable for administration.

Solid-Phase Peptide Synthesis (SPPS)

A method developed by Bruce Merrifield in which peptides are assembled on an insoluble resin support, with amino acids added one at a time from the C-terminus to the N-terminus. Each cycle involves deprotection, coupling, and washing steps. SPPS revolutionized peptide chemistry by enabling efficient synthesis and purification, and remains the standard manufacturing method for research and therapeutic peptides.

---

Aging and Longevity

Altered Intercellular Communication

A proposed hallmark of aging encompassing changes in endocrine, neural, immune, and local cell-to-cell signaling. “Altered” describes a broad research framework, not a single pathway or validated treatment target, and changes can be tissue- and context-specific.

Biological Age vs. Chronological Age

Chronological age is elapsed time since birth. “Biological age” is an estimate derived from a selected model, such as DNA-methylation, biomarker, or functional algorithms. Different clocks measure different features and can disagree; a lower clock value is not by itself proof of improved health, reversed aging, or longer life.

Cellular Senescence

A durable cell-cycle arrest triggered by stressors such as telomere dysfunction, DNA damage, or oncogene activation. Some senescent cells develop a senescence-associated secretory phenotype (SASP), but phenotype and consequences vary by cell type and context. Senolytics and senomorphics are research strategies, not one proven anti-aging treatment class.

Deregulated Nutrient Sensing

A hallmark of aging involving dysfunction in the pathways that detect and respond to nutrient availability, including insulin/IGF-1 signaling, mTOR, AMPK, and sirtuins. Paradoxically, reduced nutrient signaling (as occurs with caloric restriction) tends to extend lifespan, while chronic overactivation promotes aging. This hallmark connects metabolic disease to the aging process.

Epigenetic Drift

The progressive accumulation of changes in DNA methylation, histone modifications, and chromatin organization that occurs with aging, independent of DNA sequence changes. Epigenetic drift leads to altered gene expression patterns, loss of cell identity, and impaired cellular function. Epigenetic reprogramming (partial or full) is being explored as a strategy to reverse aspects of aging.

Genomic Instability

A hallmark of aging characterized by the accumulation of DNA damage from exogenous (UV, chemicals) and endogenous (replication errors, reactive oxygen species) sources throughout life. Despite robust DNA repair mechanisms, unrepaired damage leads to mutations, chromosomal aberrations, and gene expression changes. Genomic instability drives cellular dysfunction, cancer predisposition, and age-related decline.

Geroprotector

A research term for an intervention hypothesized to target aging mechanisms or delay age-related decline. Candidate status can be based on model organisms, biomarkers, or observational data and does not mean an intervention extends human healthspan. Epitalon and Humanin remain investigational in this context.

Hallmarks of Aging

A framework of nine (later expanded to twelve) interconnected biological processes that drive aging, as defined by Lopez-Otin et al. (2013, updated 2023). The original nine hallmarks are genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Additional hallmarks include disabled macroautophagy, chronic inflammation, and dysbiosis.

Inflammaging

Chronic, sterile, low-grade inflammation that increases with age in the absence of overt infection. Driven by senescent cells (SASP), gut barrier dysfunction, immunosenescence, and cellular debris, inflammaging elevates baseline levels of pro-inflammatory cytokines (IL-6, TNF-alpha, IL-1beta). It is a major risk factor for age-related diseases including cardiovascular disease, diabetes, neurodegeneration, and cancer.

Mitochondrial Dysfunction

A hallmark framework covering changes in mitochondrial energetics, quality control, signaling, DNA, and dynamics. SS-31 (elamipretide) and Humanin-related compounds are studied in this area, but their evidence and regulatory status must be evaluated by indication; “targets mitochondria” is not a clinical outcome.

Proteostasis (Loss of)

Proteostasis refers to the maintenance of protein homeostasis through balanced protein synthesis, folding, and degradation. A hallmark of aging, loss of proteostasis involves declining chaperone function, impaired proteasome and autophagy activity, and accumulation of misfolded and aggregated proteins. Protein aggregation diseases (Alzheimer's, Parkinson's, Huntington's) exemplify the consequences of proteostasis failure.

Senomorphics

Compounds that suppress the harmful effects of senescent cells without killing them, primarily by modulating the senescence-associated secretory phenotype (SASP). Unlike senolytics, senomorphics leave senescent cells viable but reduce their inflammatory output. Examples include rapamycin (reduces SASP through mTOR inhibition) and metformin (reduces inflammatory signaling).

Senolytics

Compounds intended to preferentially eliminate selected senescent-cell populations. Dasatinib plus quercetin and fisetin show context-dependent senolytic activity in laboratory models. Selectivity differs by cell type, and the category does not yet imply a proven general anti-aging benefit in humans.

Stem Cell Exhaustion

A hallmark framework describing age-associated changes in the abundance or function of some tissue stem and progenitor cells and their niches. The pattern differs across tissues. Growth-factor or peptide effects in a model do not establish restoration of human stem-cell function.

Telomere Attrition

A hallmark of aging in which telomeres progressively shorten with each cell division due to the end-replication problem and oxidative damage. When telomeres reach a critical length, cells enter senescence or undergo apoptosis, reducing tissue regenerative capacity. Telomere shortening rate is influenced by genetics, oxidative stress, inflammation, and can be counteracted by telomerase activity.

---

Hormones and Endocrinology

ACTH (Adrenocorticotropic Hormone)

A 39-amino-acid peptide hormone secreted by the anterior pituitary that stimulates the adrenal cortex to produce cortisol and other glucocorticoids. ACTH release is regulated by CRH from the hypothalamus and is part of the hypothalamic-pituitary-adrenal (HPA) axis stress response. ACTH also has melanocyte-stimulating activity due to sharing the first 13 amino acids with alpha-MSH.

Cortisol

The primary glucocorticoid hormone produced by the adrenal cortex in response to ACTH stimulation. Cortisol regulates glucose metabolism, suppresses immune function, and mediates the body's stress response through the HPA axis. Chronically elevated cortisol (as in Cushing's syndrome or chronic stress) promotes insulin resistance, muscle wasting, immunosuppression, and accelerated aging.

Estrogen

A group of steroid hormones (primarily estradiol, estrone, estriol) produced mainly by the ovaries (and in smaller amounts by the adrenals and adipose tissue) that regulate female reproductive development and function. Estrogen also maintains bone density, cardiovascular health, brain function, and skin elasticity. Declining estrogen at menopause contributes to osteoporosis, cardiovascular risk, and various aging-related changes.

FSH (Follicle-Stimulating Hormone)

A glycoprotein gonadotropin secreted by the anterior pituitary that stimulates follicular growth in the ovaries and spermatogenesis in the testes. FSH release is regulated by GnRH and feedback from inhibin and sex steroids. Elevated FSH levels occur in menopause and have recently been implicated in bone loss and adiposity through direct peripheral effects.

Glucagon

A 29-amino-acid peptide hormone produced by pancreatic alpha cells that raises blood glucose by promoting hepatic glycogenolysis and gluconeogenesis. Glucagon opposes the actions of insulin and is critical for preventing hypoglycemia during fasting. Dual GLP-1/glucagon receptor agonists are being developed for obesity and metabolic disease treatment.

Growth Hormone (GH)

A 191-amino-acid protein hormone secreted by anterior pituitary somatotrophs in a pulsatile pattern. GH stimulates IGF-1 production, supports linear growth in children, and affects metabolism and body composition. Secretion changes across the lifespan. Experimental secretagogues cannot be assumed to reverse normal aging or produce a “youthful” endocrine state safely.

IGF-1 (Insulin-Like Growth Factor 1)

A peptide hormone primarily produced by the liver in response to growth hormone stimulation. IGF-1 mediates many of GH's anabolic effects, promoting cell growth, proliferation, and survival through the IGF-1R and downstream PI3K/AKT and MAPK pathways. IGF-1 levels decline with age and are central to the GH/IGF-1 axis that regulates growth, metabolism, and longevity.

Insulin

A 51-amino-acid peptide hormone produced by pancreatic beta cells that is the primary regulator of blood glucose homeostasis. Insulin promotes glucose uptake into muscle and adipose tissue, stimulates glycogen synthesis, and inhibits hepatic gluconeogenesis. Insulin resistance is a hallmark of type 2 diabetes and metabolic syndrome, and the insulin/IGF-1 signaling pathway is one of the most conserved longevity-regulating pathways across species.

LH (Luteinizing Hormone)

A glycoprotein gonadotropin secreted by the anterior pituitary that triggers ovulation and progesterone production in females, and stimulates testosterone production by Leydig cells in males. LH surges are critical for reproductive function and are regulated by pulsatile GnRH input. GnRH agonists and antagonists manipulate LH secretion for fertility treatment and hormone-sensitive cancer therapy.

Melatonin

A hormone produced primarily by the pineal gland with secretion timed by the light-dark cycle. It signals circadian timing through melatonin receptors. Evidence for exogenous melatonin differs by formulation, outcome, population, and jurisdiction; antioxidant or anticancer findings in experimental systems do not establish those treatment indications.

Oxytocin

A nine-amino-acid cyclic peptide hormone synthesized in the hypothalamus and released into circulation from the posterior pituitary. It has established roles in uterine contraction and milk ejection and participates in context-dependent neural and social processes. Laboratory research on repair or aging does not create a general clinical indication.

Prolactin

A peptide hormone secreted by the anterior pituitary that primarily stimulates milk production (lactation) after childbirth. Prolactin has over 300 known biological actions including immune regulation, osmoregulation, and reproductive behavior. Elevated prolactin (hyperprolactinemia) can suppress the HPG axis, causing hypogonadism, and is commonly caused by pituitary adenomas or dopamine-blocking medications.

Somatostatin

A cyclic peptide hormone produced in the hypothalamus, pancreatic delta cells, and gastrointestinal tract that broadly inhibits hormone secretion. It suppresses growth hormone, insulin, glucagon, TSH, and numerous GI hormones. Synthetic analogs (octreotide, lanreotide) are used to treat acromegaly and neuroendocrine tumors. Somatostatin's inhibitory action opposes GHRH-stimulated GH release.

Testosterone

The primary androgen produced mainly by testicular Leydig cells in males and in smaller amounts by the adrenals and ovaries in females. Testosterone drives male reproductive development, maintains muscle mass and bone density, regulates erythropoiesis, and influences mood and cognition. Age-related testosterone decline (andropause) contributes to sarcopenia, osteoporosis, and metabolic changes.

Thyroid Hormones (T3/T4)

Iodine-containing hormones (thyroxine/T4 and triiodothyronine/T3) produced by the thyroid gland that regulate basal metabolic rate, thermogenesis, growth, and development. T4 is the predominant circulating form, converted to the more active T3 in peripheral tissues by deiodinase enzymes. Thyroid dysfunction affects virtually every organ system and is common in aging populations.

---

Disease and Condition Terms

Alzheimer's Disease

A progressive neurodegenerative disease and the most common cause of dementia, characterized pathologically by amyloid plaques and tau tangles alongside synaptic and neuronal loss. Humanin, DSIP, and Semax appear in experimental models, but model “neuroprotection” does not establish prevention or treatment of Alzheimer’s disease.

Amyotrophic Lateral Sclerosis (ALS)

A progressive neurodegenerative disease affecting upper and lower motor neurons, leading to weakness and disability. Multiple genetic and biological mechanisms are involved. A compound described as “neuroprotective” in a model is not thereby a disease-modifying ALS therapy.

Atherosclerosis

A chronic inflammatory disease of arteries characterized by the buildup of lipid-rich plaques in the vessel wall. It develops through endothelial dysfunction, LDL oxidation, macrophage foam cell formation, and smooth muscle proliferation. Atherosclerosis is the underlying cause of most heart attacks and strokes, and involves complex interactions between inflammatory cytokines, immune cells, and vascular peptides.

Cachexia

A complex metabolic syndrome characterized by severe, involuntary loss of skeletal muscle mass (with or without fat loss) that cannot be fully reversed by nutritional support. It occurs in cancer, HIV/AIDS, heart failure, and COPD, and significantly increases mortality. GH secretagogues and ghrelin mimetics (anamorelin) are studied for their ability to counteract cancer-related cachexia.

Fibrosis

The excessive accumulation of extracellular matrix components, particularly collagen, resulting in tissue scarring and organ dysfunction. Fibrosis can affect the liver (cirrhosis), lungs (pulmonary fibrosis), kidneys, heart, and skin. Key mediators include TGF-beta, activated fibroblasts/myofibroblasts, and inflammatory cytokines. Anti-fibrotic peptides are an active area of research.

Inflammatory Bowel Disease (IBD)

A group of chronic inflammatory gastrointestinal diseases, primarily Crohn’s disease and ulcerative colitis. Genetics, immune regulation, epithelial biology, environmental exposures, and the microbiome can contribute. BPC-157 and KPV appear in preclinical models, which do not establish human mucosal healing or disease control.

Ischemia

Insufficient blood flow to a tissue, reducing oxygen and nutrient delivery and potentially causing injury or infarction. Restoration of flow can add reperfusion injury through multiple mechanisms. Peptide effects in ischemia models do not establish emergency or preventive treatment in humans.

Multiple Sclerosis (MS)

An immune-mediated disease of the central nervous system involving inflammation, demyelination, and neuroaxonal injury. Course and symptoms vary. Experimental immunomodulatory or tolerogenic peptides are research approaches and should not be described as MS treatments without indication-specific human evidence and authorization.

MASLD/MASH (formerly NAFLD/NASH)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the current umbrella term for hepatic steatosis with cardiometabolic risk factors; metabolic dysfunction-associated steatohepatitis (MASH) adds inflammation and hepatocellular injury. Older literature uses NAFLD and NASH. Drug evidence must be tied to a specific liver endpoint and approved indication rather than inferred from weight loss alone.

Obesity

A chronic, heterogeneous disease in which excess or dysfunctional adiposity impairs health. Biology, environment, medications, sleep, social factors, and genetics can contribute. Semaglutide is a GLP-1 receptor agonist and tirzepatide is a dual GIP/GLP-1 receptor agonist; outcomes and indications are product- and population-specific.

Osteoporosis

A skeletal disorder characterized by reduced bone mineral density and deterioration of bone microarchitecture, leading to increased fracture risk. Osteoporosis results from an imbalance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Hormonal changes (menopause, andropause), GH/IGF-1 decline, and chronic inflammation contribute to age-related bone loss.

Parkinson's Disease

A progressive neurodegenerative disorder associated with loss of dopaminergic neurons in the substantia nigra and motor and non-motor symptoms. Alpha-synuclein pathology is a common hallmark. “Neuroprotection” in cells or animals does not establish disease modification in people.

Retinitis Pigmentosa

A group of inherited retinal dystrophies involving progressive photoreceptor dysfunction and loss. The causal gene, phenotype, and progression vary. Experimental neurotrophic or peptide approaches must be evaluated by the exact genotype, product, route, and human outcome—not by a shared “neuroprotective” label.

Sarcopenia

A muscle disease characterized by low muscle strength with reduced muscle quantity or quality and impaired performance in more severe cases. Risk and progression reflect age, activity, nutrition, illness, and other factors. Experimental GH-axis, myostatin, or follistatin approaches are not interchangeable with clinically validated management.

Type 2 Diabetes

A metabolic disease involving hyperglycemia, insulin resistance, and beta-cell dysfunction, influenced by genetic, environmental, and behavioral factors. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. Benefits and risks depend on the exact approved product, indication, and patient context.

---

Research Methods

Double-Blind Study

A clinical trial design in which neither the participants nor the investigators know which treatment (active drug or placebo) each participant is receiving until the study is complete. Double-blinding minimizes expectation bias and observer bias, strengthening the validity of study findings. It is considered the gold standard in clinical trial methodology.

ED50

The effective dose of a drug that produces the desired therapeutic effect in 50% of the test population. ED50 is used to establish dose-response relationships in vivo and is distinct from EC50, which is determined in vitro. The ratio of LD50 to ED50 provides the therapeutic index, a measure of drug safety.

ELISA (Enzyme-Linked Immunosorbent Assay)

A plate-based assay technique used to detect and quantify peptides, proteins, antibodies, and hormones. ELISA uses antibody-antigen interactions and enzyme-linked color reactions for detection. It is widely used in peptide research to measure hormone levels, cytokine concentrations, and biomarker quantities in biological samples.

Ex Vivo

Experiments conducted on tissue taken from a living organism and studied in an external environment with minimal alteration of natural conditions. Ex vivo approaches bridge the gap between in vitro cell culture and in vivo whole-organism studies, maintaining tissue architecture and cell-cell interactions while allowing controlled experimental manipulation.

Flow Cytometry

A technique that passes cells in a fluid stream through a laser beam to measure physical and chemical characteristics of cell populations. Fluorescent antibodies or dyes label specific cell surface markers or intracellular proteins, enabling identification and quantification of cell types, cell cycle analysis, and apoptosis detection. It is essential in immunology research for characterizing immune cell populations.

Immunohistochemistry (IHC)

A technique that uses antibodies to detect specific proteins in tissue sections, allowing visualization of protein expression and localization in their anatomical context. IHC is combined with microscopy to examine receptor distribution, cell type identification, and disease pathology. It is widely used in cancer diagnosis and peptide receptor mapping in research.

In Vitro

Experiments performed outside a living organism, typically in test tubes, cell culture plates, or other laboratory vessels. In vitro studies allow controlled investigation of specific biological mechanisms but may not fully reflect the complexity of in vivo responses. Cell-based assays, receptor binding studies, and enzyme kinetics are common in vitro approaches in peptide research.

In Vivo

Experiments conducted within a living organism. Animal in vivo studies can examine whole-organism exposure, distribution, metabolism, and selected safety or biological outcomes. They are more physiologically integrated than isolated assays but remain preclinical and do not reliably predict every human benefit or harm.

LD50

The lethal dose of a substance that kills 50% of a test animal population, a measure of acute toxicity. LD50 testing has become less common due to ethical concerns and has been partially replaced by alternative methods. When reported, LD50 helps establish the margin of safety for a compound and is used in the calculation of the therapeutic index.

PCR (Polymerase Chain Reaction)

A technique that amplifies specific DNA sequences millions of times using cycles of denaturation, primer annealing, and DNA polymerase extension. Quantitative PCR (qPCR) measures gene expression levels, while reverse-transcription PCR (RT-PCR) first converts mRNA to cDNA. PCR is used in peptide research to measure gene expression changes in response to peptide treatment.

Phase I / II / III Clinical Trials

Common stages of clinical drug development, although phases can overlap or be combined. Phase 1 generally emphasizes initial human pharmacology and safety; phase 2 gathers preliminary effectiveness and short-term safety data in people with the condition; phase 3 expands evidence about effectiveness and benefit-risk in larger populations. A trial’s phase is not a quality grade and does not itself mean the product is approved.

Placebo-Controlled

A study design in which the control group receives an inactive treatment (placebo) identical in appearance to the active treatment. Comparing outcomes between active and placebo groups isolates the drug's true effect from the placebo response and natural disease course. Placebo-controlled trials are essential for establishing efficacy, particularly for subjective endpoints.

Randomized Controlled Trial (RCT)

A design in which participants are assigned to groups by a random process. Proper randomization reduces systematic baseline differences, while allocation concealment, blinding, outcome selection, attrition, sample size, and analysis still affect reliability. RCTs are strong tools for estimating causal effects, but one RCT does not automatically establish effectiveness or characterize rare and long-term harms.

Western Blot

A laboratory technique used to detect specific proteins in a tissue homogenate or cell lysate by separating proteins by size through gel electrophoresis, transferring them to a membrane, and probing with specific antibodies. Western blotting is used in peptide research to assess protein expression levels, post-translational modifications, and signaling pathway activation (phospho-specific antibodies).

---

Common Acronyms in Peptide Research

BBB (Blood-Brain Barrier)

The selective permeability barrier formed by brain capillary endothelial cells joined by tight junctions, pericytes, and astrocyte end-feet. The BBB prevents most blood-borne substances from entering the brain while allowing essential nutrients and gases to pass. It represents a major challenge for CNS drug delivery, and peptide-based transport strategies (shuttle peptides, receptor-mediated transcytosis) are being developed to cross it.

CNS (Central Nervous System)

The brain and spinal cord, which integrate sensory information and coordinate motor, autonomic, and cognitive functions. The CNS contains neurons, astrocytes, oligodendrocytes, microglia, and other cell types. Compounds such as Semax, Selank, Cerebrolysin, and Dihexa are promoted for CNS outcomes, but their classifications and clinical evidence differ; see the brain-peptide evidence guide.

DPP-IV (Dipeptidyl Peptidase-4)

A serine protease that rapidly degrades incretin hormones (GLP-1 and GIP) by cleaving the N-terminal dipeptide. DPP-IV inhibitors (sitagliptin, saxagliptin) are oral diabetes medications that prolong endogenous incretin activity. DPP-IV resistance is a key feature engineered into long-acting GLP-1 receptor agonists like semaglutide and liraglutide.

ECM (Extracellular Matrix)

The non-cellular structural framework composed of proteins and polysaccharides that surrounds cells in tissues. The ECM provides physical scaffolding, biochemical signaling, and mechanical cues. Peptides including GHK-Cu are studied in ECM-related models, but effects depend on route and evidence level; see the GHK-Cu guide.

EMA (European Medicines Agency)

The regulatory body responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union. EMA's Committee for Medicinal Products for Human Use (CHMP) issues marketing authorization opinions for drug approval. EMA and FDA harmonize many regulatory standards but maintain independent approval processes.

FDA (Food and Drug Administration)

The United States federal agency responsible for regulating drugs, biologics, medical devices, food safety, and cosmetics. The FDA's approval process requires demonstration of safety and efficacy through preclinical studies and phased clinical trials. FDA-approved peptide therapeutics include semaglutide, insulin analogs, teriparatide, and numerous others.

GI (Gastrointestinal)

Relating to the gastrointestinal tract, the organ system involved in digestion, absorption, and waste elimination. The GI tract produces peptide hormones including GLP-1, GIP, ghrelin, and cholecystokinin and presents enzymatic and permeability barriers to oral peptide delivery. BPC-157 is studied in gastrointestinal models, but human therapeutic evidence remains limited; see the BPC-157 guide.

GRAS (Generally Recognized as Safe)

A U.S. food-law concept under which qualified experts generally recognize a substance as safe under the conditions of its intended food use. GRAS status is not blanket safety, FDA approval of a drug, or authorization for injection, compounding, disease treatment, or a different exposure condition.

HPA Axis (Hypothalamic-Pituitary-Adrenal Axis)

The neuroendocrine system linking the hypothalamus (CRH), anterior pituitary (ACTH), and adrenal cortex (cortisol) that coordinates the body's stress response. HPA axis activation increases cortisol to mobilize energy and suppress inflammation. Chronic HPA axis dysregulation (from prolonged stress) contributes to immune suppression, metabolic dysfunction, and accelerated aging.

HPG Axis (Hypothalamic-Pituitary-Gonadal Axis)

The neuroendocrine system linking the hypothalamus (GnRH), anterior pituitary (FSH, LH), and gonads (testosterone, estrogen) that regulates reproductive function. Pulsatile GnRH secretion maintains HPG axis activity, while continuous GnRH exposure causes desensitization. HPG axis decline with aging contributes to menopause, andropause, and associated metabolic changes.

IFN-gamma (Interferon Gamma)

A cytokine produced primarily by T-cells and NK cells that is critical for innate and adaptive immunity. IFN-gamma activates macrophages, enhances antigen presentation, promotes Th1 immune responses, and has direct antiviral and antitumor activity. It is used therapeutically in chronic granulomatous disease and is modulated by immunomodulatory peptides including thymosin alpha-1.

IL-1 / IL-2 / IL-6 / IL-10 (Interleukins)

A family of cytokines that mediate communication between immune cells. IL-1 is a pro-inflammatory mediator in innate immunity and inflammasome activation. IL-2 drives T-cell proliferation and is used in cancer immunotherapy. IL-6 has both pro- and anti-inflammatory roles and is elevated in chronic inflammation and aging. IL-10 is a potent anti-inflammatory cytokine that suppresses immune activation and maintains tissue homeostasis.

MMP (Matrix Metalloproteinase)

A family of zinc-dependent endopeptidases that degrade extracellular matrix components. MMPs (collagenases, gelatinases, stromelysins) play essential roles in tissue remodeling, wound healing, and angiogenesis. Excessive MMP activity contributes to cancer metastasis, arthritis, and skin aging. MMP activity is balanced by tissue inhibitors of metalloproteinases (TIMPs) and is influenced by peptides including GHK-Cu.

NO (Nitric Oxide)

A short-lived signaling molecule produced by nitric oxide synthase enzymes. NO participates in vascular tone, neurotransmission, immune responses, and platelet biology. Changes in an NO-related marker or animal pathway do not establish a cardiovascular or tissue-healing effect in humans.

PK/PD (Pharmacokinetics/Pharmacodynamics)

The integrated study of drug concentration-time profiles (PK) and concentration-effect relationships (PD). PK/PD modeling characterizes how a drug's absorption, distribution, metabolism, and excretion relate to its therapeutic and toxic effects over time. Understanding PK/PD is essential for peptide dose optimization, particularly given the rapid clearance and short half-lives of most peptides.

PNS (Peripheral Nervous System)

Neural structures outside the brain and spinal cord, including peripheral nerves and much of the autonomic nervous system. The PNS carries sensory, motor, and autonomic signals. Nerve-growth factors and experimental peptides are studied in peripheral-nerve models; model findings are not proof of clinical repair or regeneration.

ROS (Reactive Oxygen Species)

Chemically reactive molecules containing oxygen, including superoxide, hydrogen peroxide, and hydroxyl radicals, generated as byproducts of mitochondrial respiration and by specific enzymes (NADPH oxidase). While low-level ROS serve as signaling molecules, excessive ROS cause oxidative damage to DNA, proteins, and lipids. Antioxidant defense systems (SOD, catalase, glutathione, Nrf2 pathway) counteract ROS, and oxidative stress is implicated in aging and numerous diseases.

SNAC (Sodium N-[8-(2-Hydroxybenzoyl)Amino] Caprylate)

An absorption enhancer used in a specific approved oral semaglutide formulation. Its formulation-dependent effects include local buffering and increased gastric absorption. Evidence for that co-formulated product does not show that SNAC makes unrelated peptides orally bioavailable.

TNF-alpha (Tumor Necrosis Factor Alpha)

A pro-inflammatory cytokine produced primarily by macrophages that plays central roles in systemic inflammation, immune regulation, and apoptosis. TNF-alpha activates NF-kappaB signaling and is a key mediator in autoimmune diseases (rheumatoid arthritis, IBD, psoriasis). TNF inhibitors (infliximab, adalimumab, etanercept) are among the most commercially successful biologic therapies.

VEGF (Vascular Endothelial Growth Factor)

A signaling protein family (VEGF-A, -B, -C, -D, PlGF) that stimulates angiogenesis, the formation of new blood vessels from existing vasculature. VEGF-A binding to VEGFR2 is the primary angiogenic signal, promoting endothelial cell proliferation, migration, and survival. Anti-VEGF therapies (bevacizumab, ranibizumab) are used in cancer and retinal diseases, while pro-angiogenic approaches are explored for ischemic tissue repair.

Continue from a term to the evidence

• How we grade evidence
• Peptide receptor guide
• Peptide bioavailability guide
• How peptides are made
• Peptide purification guide
• Peptide purity testing guide
• Evidence by use case
• Source availability and batch-record directory

References

These sources provide the terminology and regulatory framework used for this glossary. Individual treatment claims still require product- and indication-specific evidence.

1. International Union of Pure and Applied Chemistry. Peptides. Compendium of Chemical Terminology (Gold Book). 2025.
2. U.S. Food and Drug Administration. The Drug Development Process.
3. U.S. Food and Drug Administration. Preclinical Research.
4. U.S. Food and Drug Administration. Clinical Research.
5. U.S. Food and Drug Administration. FDA Drug Review.
6. U.S. Food and Drug Administration. Generally Recognized as Safe (GRAS).
7. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A.

Editorial note

This glossary favors concise operational definitions over promotional descriptions. A compound name used as an example does not imply approval, equivalence between products, or a recommendation to buy or use it. Regulatory status and clinical evidence can change, so follow the linked evidence guide and current regulator source before relying on a term in a health decision.